Long-term outcomes of ixekizumab treatment in patients with axial spondyloarthritis
Authors:
K. Bubová
Authors‘ workplace:
Revmatologický ústav Praha a Revmatologická klinika 1. LF UK, Praha
Published in:
Čes. Revmatol., 31, 2023, No. 3, p. 145-150.
Category:
Úvodník
Overview
|
145 |
Axial spondyloarthritis (axSpA) is a systemic inflammatory disease that can significantly contribute to the deterioration of the quality of life. That is why nowadays the emphasis is placed on early diagnosis and initiation of treatment. Ixekizumab is an inhibitor of interleukin (IL)-17A, which has shown good efficacy with long-term efficacy in patients with a radiographic form of the disease (r-axSpA) who were naïve to the use of biological treatment, in patients treated with tumor necrosis factor inhibitors (TNFi), and in non-radiographic (nr-axSpA) patients. In addition, current three-year follow-up data from the COAST studies did not show significant changes in the safety profile compared to previously reported adverse events. In addition, 89.6% of patients with r-axSpA had stable radiographic findings after 2 years, which is similar to the results of other IL-17 inhibitors. However, it should be noted that radiographic progression in axSpA is slow and the minimum time needed to evaluate it is 2 years. Therefore, a multi-year follow-up is needed so that the effect on radiographic progression can be fully demonstrated.
Keywords:
ixekizumab – axial spondyloarthritis – IL-17 inhibitors
Sources
- Pavelka K, Výbor České Revmatologické Společnosti. Doporučení České revmatologické společnosti pro farmakologickou léčbu axiálních spondyloartritid Část I. Strategie léčby a farmakoterapie. Čes Revmatol 2021; 2021(1): 5–19.
- Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both? Rheumatology 2018; 57(7): 1145–1150.
- Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, et al.; COAST-X Study Group. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 2020; 395(10217): 53–64.
- van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, et al.; COAST-V study group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018; 392 (10163): 2441–2451.
- Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, et al.; COAST-V and COAST-W Study Groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 2020; 79(2): 176–185.
- Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol 2023; 50(8): 1020–1028.
- Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, et al.; COAST-Y study group. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo--controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis 2021; 80(8): 1022–1030.
- Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, et al. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open 2022; 8(2): e002165.
- Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020; 79: 1132–1138.
- Fabiani C, Vitale A, Lopalco G, Iannone F, Frediani B, Cantarini L. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 2016; 35(11): 2631–2638.
- van der Horst-Bruinsma IE, Robinson PC, Favalli EG, Verbraak FD, Kim M, Kumke T, et al. Certolizumab pegol treatment in patients with axial-spondyloarthritis-associated acute anterior uveitis: a narrative review. Rheumatol Ther 2022; 9(6): 1481–1497.
- van der Heijde D, Østergaard M, Reveille JD, Baraliakos X, Kronbergs A, Sandoval DM, et al. Spinal radiographic progression and predictors of progression in patients with radiographic axial spondyloarthritis receiving ixekizumab over 2 years. J Rheumatol 2022; 49(3): 265–273.
- Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 2023; 82(1): 130–141.
- Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017; 76: 1070–1077.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2023 Issue 3
Most read in this issue
- The anniversary of chief radiologist Jindra Gatterová
- Septic arthritis in light of the guidelines of the French Society for Rheumatology
- Quo vadis dětská revmatologie?
- Pain in axial spondyloarthritis – causes, evaluation, differential diagnosis and therapy options